193 related articles for article (PubMed ID: 15493002)
1. Clinical use of positron emission tomography in the management of cutaneous melanoma.
Friedman KP; Wahl RL
Semin Nucl Med; 2004 Oct; 34(4):242-53. PubMed ID: 15493002
[TBL] [Abstract][Full Text] [Related]
2. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
Kumar R; Alavi A
Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Prognostic Value of
Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
[TBL] [Abstract][Full Text] [Related]
5. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node.
Wagner T; Meyer N; Zerdoud S; Julian A; Chevreau C; Payoux P; Courbon F
Br J Dermatol; 2011 Jun; 164(6):1235-40. PubMed ID: 21332457
[TBL] [Abstract][Full Text] [Related]
6.
Jaeger ZJ; Williams GA; Chen L; Mhlanga JC; Cornelius LA; Fields RC
J Surg Oncol; 2022 Mar; 125(3):525-534. PubMed ID: 34741547
[TBL] [Abstract][Full Text] [Related]
7. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
8. [Role of FDG PET-CT in cutaneous melanoma].
Nicol I; Chuto G; Gaudy-Marqueste C; Brenot-Rossi I; Grob JJ; Richard MA
Bull Cancer; 2008 Nov; 95(11):1089-101. PubMed ID: 19036682
[TBL] [Abstract][Full Text] [Related]
9. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence.
Abbott RA; Acland KM; Harries M; O'Doherty M
Melanoma Res; 2011 Oct; 21(5):446-9. PubMed ID: 21849913
[TBL] [Abstract][Full Text] [Related]
10. Fluorodeoxyglucose-PET in the management of malignant melanoma.
Kumar R; Mavi A; Bural G; Alavi A
Radiol Clin North Am; 2005 Jan; 43(1):23-33. PubMed ID: 15693645
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
[TBL] [Abstract][Full Text] [Related]
12. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis.
Rodriguez Rivera AM; Alabbas H; Ramjaun A; Meguerditchian AN
Surg Oncol; 2014 Mar; 23(1):11-6. PubMed ID: 24556310
[TBL] [Abstract][Full Text] [Related]
13. Guidelines for lymphoscintigraphy and F18 FDG PET scans in melanoma.
Uren RF; Howman-Giles R; Chung D; Thompson JF
J Surg Oncol; 2011 Sep; 104(4):405-19. PubMed ID: 21858836
[TBL] [Abstract][Full Text] [Related]
14. Role of FDG-PET in the assessment of survival prognosis in melanoma.
Pleiss C; Risse JH; Biersack HJ; Bender H
Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
[TBL] [Abstract][Full Text] [Related]
15. Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients.
Helvind NM; Weitemeyer MB; Chakera AH; Hendel HW; Ellebæk E; Svane IM; Kjærskov MW; Bojesen S; Skyum H; Petersen SK; Bastholt L; Johansen C; Bidstrup PE; Hölmich LR
Ann Surg Oncol; 2023 Apr; 30(4):2377-2388. PubMed ID: 36752970
[TBL] [Abstract][Full Text] [Related]
16. FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer.
Siggelkow W; Rath W; Buell U; Zimny M
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S118-24. PubMed ID: 15146295
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
[TBL] [Abstract][Full Text] [Related]
18. No benefit in staging fluorodeoxyglucose-positron emission tomography in clinically node-negative head and neck cutaneous melanoma.
Bikhchandani J; Wood J; Richards AT; Smith RB
Head Neck; 2014 Sep; 36(9):1313-6. PubMed ID: 23956077
[TBL] [Abstract][Full Text] [Related]
19. Positron Emission Tomography/Computed Tomography Transformation of Oncology: Melanoma and Skin Malignancies.
Lee ST; Kovaleva N; Senko C; Kee D; Scott AM
PET Clin; 2024 Apr; 19(2):231-248. PubMed ID: 38233284
[TBL] [Abstract][Full Text] [Related]
20. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma.
Clark PB; Soo V; Kraas J; Shen P; Levine EA
Arch Surg; 2006 Mar; 141(3):284-8. PubMed ID: 16549694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]